3:47 PM
Feb 06, 2018
 |  BC Extra  |  Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

In a study published in Proceedings of the National Academy of Sciences, the co-founders of Ilya Pharma AB (Uppsala, Sweden) showed topical delivery of Lactobacillus reuteri engineered to express chemokine CXC motif ligand 12 (CXCL12; SDF-1) could accelerate wound healing. The company plans to start clinical trials by year end.


Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >